Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 15.00M | 0.00 | 0.00 | 0.00 | Gross Profit |
-33.00K | -2.41M | 6.65M | -734.00K | -121.00K | 0.00 | EBIT |
-58.61M | -73.11M | -105.64M | -60.44M | -13.50M | -29.00K | EBITDA |
-58.55M | -122.24M | -97.29M | -70.03M | -68.21M | -29.00K | Net Income Common Stockholders |
-49.77M | -124.65M | -101.05M | -70.76M | -68.37M | -109.00K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
19.82M | 185.86M | 268.23M | 376.98M | 19.82M | 6.00K | Total Assets |
22.56M | 188.46M | 321.90M | 401.99M | 22.56M | 6.00K | Total Debt |
0.00 | 362.00K | 5.79M | 0.00 | 0.00 | 2.21M | Net Debt |
-19.82M | -185.50M | -41.94M | -376.98M | -19.82M | 2.20M | Total Liabilities |
32.36M | 4.87M | 25.61M | 12.14M | 32.36M | 2.22M | Stockholders Equity |
-9.80M | 183.58M | 296.29M | 389.84M | -9.80M | -2.22M |
Cash Flow | Free Cash Flow | ||||
-59.86M | -100.86M | -94.57M | -58.59M | -10.27M | -19.00K | Operating Cash Flow |
-59.39M | -90.01M | -87.98M | -52.85M | -8.72M | -19.00K | Investing Cash Flow |
-154.48M | 226.35M | -241.86M | -5.74M | -1.54M | 0.00 | Financing Cash Flow |
199.00M | 190.00K | 597.00K | 417.47M | 30.08M | 0.00 |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
49 Neutral | $519.43M | ― | -23.34% | ― | 47.92% | 17.84% | |
49 Neutral | $740.82M | ― | -194.63% | ― | -35.50% | 3.81% | |
48 Neutral | $852.20M | ― | 34.94% | ― | ― | ― | |
46 Neutral | $788.01M | ― | -25.68% | ― | ― | 68.93% | |
40 Underperform | $792.26M | ― | -54.14% | ― | ― | 6.99% | |
39 Underperform | $697.75M | ― | -50.50% | ― | ― | 4.28% |
LENZ Therapeutics is hosting a Commercial Day on April 15, 2025, to provide updates on the potential approval and launch of LNZ100. The event will cover commercialization strategies, supply chain readiness, and insights from Key Opinion Leaders and Eye Care Professionals.
Spark’s Take on LENZ Stock
According to Spark, TipRanks’ AI Analyst, LENZ is a Underperform.
LENZ Therapeutics faces significant financial challenges with persistent losses and negative cash flows, despite a strong equity position. The negative P/E ratio and lack of dividend suggest a high-risk valuation. Technical indicators further highlight bearish sentiment. However, positive strides in regulatory progress and a promising future outlook from the earnings call provide some optimism. Investors should weigh these risks against potential long-term rewards.
To see Spark’s full report on LENZ stock, click here.